Company Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States.
It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy.
It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor.
The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer.
I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 17, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 220 |
| CEO | Xi-Yong Fu |
Contact Details
Address: 2440 Research Boulevard, Suite 400 Rockville, Maryland 20850 United States | |
| Phone | 240 745 6330 |
| Website | ir.i-mabbiopharma.com |
Stock Details
| Ticker Symbol | IMAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001778016 |
| CUSIP Number | 44975P103 |
| ISIN Number | US44975P1030 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Xi-Yong Fu M.B.A., Ph.D. | Chief Executive Officer and Director |
| Skelton Joseph | Chief Financial Officer |
| Tianyi Zhang | Vice President of Investor Relations |
| Dr. Fernando J. Salle´s Ph.D. | Senior Vice President and Head of U.S. and EU Business Development |
| Dr. Louie Naumovski M.D., Ph.D. | Interim Chief Medical Officer |
| Dr. Phillip Dennis M.D., Ph.D. | Chief Medical Officer |
| Tyler Ehler | Senior Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 6-K | Report of foreign issuer |
| Nov 6, 2024 | 6-K | Report of foreign issuer |
| Nov 5, 2024 | 6-K | Report of foreign issuer |
| Oct 24, 2024 | 6-K | Report of foreign issuer |
| Sep 23, 2024 | 6-K | Report of foreign issuer |
| Sep 16, 2024 | 6-K | Report of foreign issuer |
| Aug 30, 2024 | 6-K | Report of foreign issuer |
| Aug 28, 2024 | 6-K | Report of foreign issuer |
| Aug 7, 2024 | 6-K | Report of foreign issuer |
| Jul 26, 2024 | 144 | Filing |